腎臓がん治療薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Kidney Cancer Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Product Profiles
05.1.1 Nexavar
05.1.2 Avastin
05.1.3 Votrient
05.1.4 Afinitor/Votubia
05.1.5 Proleukin
05.1.6 Inlyta
05.1.7 Sutent
05.1.8 Torisel

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.1.1 Types of Kidney Cancer
07.1.2 Benign Kidney Tumors
07.2 Risk Factors
07.2.1 Lifestyle and Job-related Risk Factors
07.2.2 Genetic and Hereditary Risk Factors
07.2.3 Other Risk Factors
07.3 Etiology and Pathogenesis
07.3.1 Inherited Gene Mutations
07.3.2 Acquired Gene Mutations
07.4 Signs and Symptoms
07.5 Diagnosis
07.5.1 Medical History and Physical Exam
07.5.2 Lab Tests
07.5.3 Imaging Tests
07.5.4 Biopsy
07.6 Staging
07.6.1 TNM Staging System
07.7 Management
07.7.1 Surgery
07.7.2 Ablation and Other Local Therapies
07.7.3 Radiation Therapy
07.7.4 Targeted Therapy
07.7.5 Biologic Therapy (Immunotherapy)
07.7.6 Chemotherapy
07.8 Epidemiology
07.9 Economic Burden

08.Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 AGS-003
08.1.2 Rencarex
08.1.3 Cometriq
08.1.4 IMA901
08.1.5 AV-951
08.1.6 TroVax
08.1.7 MPDL3280A
08.1.8 Opdivo
08.1.9 Naptumomab Estafenatox
08.1.10 Carfilzomib

09.Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis

10.Market Segmentation by Molecule Type
10.1 Small Molecules
10.2 Biologics

11.Geographical Segmentation

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and Their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and Their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Bayer
19.2.2 F. Hoffmann-La Roche
19.2.3 GlaxoSmithKline
19.2.4 Novartis
19.2.5 Pfizer
19.3 Other and Future Prominent Vendors

20.Global Kidney Cancer Drugs Market: Key Takeaways

21.Key Vendor Analysis
21.1 Bayer
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2014
21.1.4 Business Segmentation by Revenue 2013 and 2014
21.1.5 Geographical Segmentation by Revenue 2014
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2014
21.3.4 Business Segmentation by Revenue 2013 and 2014
21.3.5 Geographical Segmentation by Revenue 2014
21.3.6 Business Strategy
21.3.7 Recent Developments
21.3.8 SWOT Analysis
21.4 Novartis
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Pfizer
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2014
21.5.4 Business Segmentation by Revenue 2013 and 2014
21.5.5 Geographical Segmentation by Revenue 2014
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis

22.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Types of Kidney Cancer
Exhibit 3: Types of Benign Kidney Tumor
Exhibit 4: Prevalence of Kidney Cancer by Gender
Exhibit 5: Global Kidney Cancer Drugs Market: Pipeline Portfolio
Exhibit 6: Global Kidney Cancer Drugs Market 2014-2019 ($ billions)
Exhibit 7: Segmentation of Global Kidney Cancer Drugs Market by Molecule Type
Exhibit 8: Segmentation of Global Kidney Cancer Drugs Market by Geography 2014
Exhibit 9: Major Drivers in Global Kidney Cancer Drugs Market
Exhibit 10: Major Challenges in Global Kidney Cancer Drugs Market
Exhibit 11: Major Trends of Global Kidney Cancer Drugs Market
Exhibit 12: Bayer: YoY Growth and Revenue of Nexavar 2010-2014 ($ millions)
Exhibit 13: F. Hoffmann-La Roche: YoY Growth and Revenue of Avastin 2010-2014 ($ millions)
Exhibit 14: GlaxoSmithKline: YoY Growth and Revenue of Votrient 2010-2014 ($ millions)
Exhibit 15: GlaxoSmithKline: Revenue of Votrient by Region 2010-2014 ($ millions)
Exhibit 16: Novartis: YoY Growth and Revenue of Afinitor 2010-2014 ($ millions)
Exhibit 17: Novartis: Revenue of Afinitor by Region 2012-2013 ($ millions)
Exhibit 18: Novartis: YoY Growth and Revenue of Proleukin 2012-2014 ($ millions)
Exhibit 19: Pfizer: YoY Growth and Revenue of Inlyta 2012-2014 ($ millions)
Exhibit 20: Pfizer: YoY Growth and Revenue of Sutent 2010-2014 ($ millions)
Exhibit 21: Global Kidney Cancer Drugs Market: Key Takeaways
Exhibit 22: Bayer: Business Segmentation by Revenue 2014
Exhibit 23: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 24: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche 2013
Exhibit 26: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: GlaxoSmithKline: Business Segmentation by Revenue 2014
Exhibit 30: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 31: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
Exhibit 32: Novartis: Business Segmentation
Exhibit 33: Novartis: Revenue by Business Segmentation 2013
Exhibit 34: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 35: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 36: Pfizer: Business Segmentation by Revenue 2014
Exhibit 37: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 38: Pfizer: Geographical Segmentation by Revenue 2014


【レポート販売概要】

■ タイトル:腎臓がん治療薬の世界市場2015-2019
■ 英文:Global Kidney Cancer Drugs Market 2015-2019
■ 発行日:2015年7月1日
■ 調査会社:Technavio
■ 商品コード:IRTNTR6298
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。